My research group aims to develop novel therapeutics at the interface of immunology, pharmaceutics, and engineering. Specifically, we are developing drug delivery systems designed to enhance delivery of antigen and adjuvant to lymphoid organs and manipulate immune functions in the context of vaccines and immunotherapies against cancer, infectious pathogens, and autoimmune disorders. Our work focusing on the development of nanotechnologies for vaccination has been published in Nature Materials, Nature Medicine, Nature Reviews Materials, Nature Biomedical Engineering, Nature Communications, PNAS, ACS Nano, Sci Transl Med, and Science Advances. Our work has also led to 18 U.S. issued or pending patent applications as well as two startup biotech companies.